Abstract:INTRODUCTION Despite advances in the understanding of the pathophysiology of the disease, clinical outcomes and quality of life of individuals with heart failure with preserved ejection fraction (HFpEF) remain poor. The role of a comorbidity-driven systemic inflammation has emerged as an important mechanism involved in profibrotic activation in HFpEF, and therefore as a promising therapeutic target in this setting. Inflammation also promotes myocardial damage due to epicardial coronary artery disease (CAD), coronary microvascular dysfunction (CMD), or both, thus reinforcing its role as a potential therapeutic target in patients with HFpEF in whom currently approved therapies are not aimed at reducing inflammation. Colchicine is an anti-inflammatory agent that has shown benefits in CAD. In HFpEF, colchicine may improve fibrosis through inhibition of inflammatory pathway implicated in both myocardial damage and CAD/CMD progression. HYPOTHESIS We hypothesize that colchicine, compared to placebo, will reduce circulating levels of biomarkers of inflammation in patients with HFpEF. Secondary questions include the effects of colchicine on biomarkers of hemodynamic stress and myocardial damage, CMD and functional status. Two dosing regimens will be compared as there is no data that have validated the appropriate dose of colchicine for HF indications. METHODS In a randomized, blinded, multiple-dose placebo-controlled clinical trial, we aim to study the effects of colchicine on inflammation in patients with HFpEF. The primary endpoint will be the change between baseline and 6 months in high-sensitivity C-reactive protein with colchicine vs. placebo. Secondary objectives will be the change between baseline and 6 months in 1) NT-pro brain natriuretic peptide and high sensitivity troponin and 2) coronary flow reserve, a marker of CMD, assessed using adenosine-based positron emission tomography imaging. Tertiary objectives will be the change between baseline and 6 months in NYHA class and six-minute walk test. A total of 426 participants will be randomly assigned in a 1:1:1 ratio to receive a 6-month course of colchicine at a dose of 0.5mg twice daily (high dose arm providing maximal inflammatory inhibition), colchicine at a dose of 0.5mg once daily (low dose arm as in CAD trials), or placebo. Follow-up will occur at 3 and 6 months after randomization. Recruitment will occur through an existing HF collaboration across Québec. EXPECTED OUTCOMES The causal role of a comorbidity-driven systemic pro-inflammatory state has recently emerged as an important mechanism involved in HFpEF, and therefore as a promising therapeutic target in this setting. This study is aimed at validating the proinflammatory/profibrotic hypothesis in HFpEF using colchicine, an anti-inflammatory medication. We expect that colchicine, on a background of standard of care, will allow for a significant reduction in circulating markers of inflammation and myocardial damage in patients with HFpEF. We also expect an improvement in CMD and functional status in patients treated with colchicine.

GEF-H1 Is Required for Colchicine Inhibition of Neutrophil Rolling and Recruitment in Mouse Models of Gout

Colchicine Inhibits Monosodium Urate Crystal-Mediated Inflammation by Influencing F-actin Formation

Identification of Glycine Receptor Α3 As a Colchicine-Binding Protein.

How to regulate neutrophils in gout

Design and Biological Evaluation of Colchicine-CD44-Targeted Peptide Conjugate in an In Vitro Model of Crystal Induced Inflammation

Transdermal delivery of colchicine using dissolvable microneedle arrays for the treatment of acute gout in a rat model

Caspase-11 Mediates Neutrophil Chemotaxis and Extracellular Trap Formation During Acute Gouty Arthritis Through Alteration of Cofilin Phosphorylation

Colchicine Impacts Leukocyte Trafficking in Atherosclerosis and Reduces Vascular Inflammation

Inhibition of CYP1A1 Alleviates Colchicine-Induced Hepatotoxicity

Colchicine derivatives inhibit neopterin production in human peripheral blood mononuclear cells (PBMC)

Combination of Colchicine and Ticagrelor Inhibits Carrageenan-Induced Thrombi in Mice

Myeloid Src-family kinases are critical for neutrophil-mediated autoinflammation in gout and motheaten models

Colchicine in Renal Medicine: New Virtues of an Ancient Friend

Brief report: Granulocyte-macrophage colony-stimulating factor drives monosodium urate monohydrate crystal-induced inflammatory macrophage differentiation and NLRP3 inflammasome up-regulation in an in vivo mouse model

A New Insight into Toxicity of Colchicine Analogues by Molecular Docking Analysis Based on Intestinal Tight Junction Protein ZO-1

Abstract 11735: the Effect of Different NLRP3 Inflammasome Inhibitors on High-Sensitivity C-reactive Protein in Patients after Percutaneous Coronary Intervention

Colchicine down-regulates lipopolysaccharide-induced granulocyte-macrophage colony-stimulating factor production in murine macrophages.

Metabolomics reveals that sulfotransferase 1 may regulate colchicine-induced liver injury

P2Y6 Receptor Antagonist MRS2578 Inhibits Neutrophil Activation and Aggregated Neutrophil Extracellular Trap Formation Induced by Gout-Associated Monosodium Urate Crystals

Effects Of Colchicine On Inflammation, Myocardial Damage And Microvascular Dysfunction In Men And Women With Heart Failure With Preserved Ejection Fraction

Colchicine Pharmacokinetics and Mechanism of Action.